Cargando…
Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?
BACKGROUND: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed. OBJECTIVES: The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904339/ https://www.ncbi.nlm.nih.gov/pubmed/27307968 http://dx.doi.org/10.5812/ijp.4008 |
_version_ | 1782437129790423040 |
---|---|
author | Tacyildiz, Nurdan Tanyildiz, Hikmet Gulsah Dincaslan, Handan Ugur Yavuz, Gulsan Unal, Emel Ozkan, Elgin Soydal, Cigdem Kucuk, Ozlem Yildiz, Yusuf |
author_facet | Tacyildiz, Nurdan Tanyildiz, Hikmet Gulsah Dincaslan, Handan Ugur Yavuz, Gulsan Unal, Emel Ozkan, Elgin Soydal, Cigdem Kucuk, Ozlem Yildiz, Yusuf |
author_sort | Tacyildiz, Nurdan |
collection | PubMed |
description | BACKGROUND: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed. OBJECTIVES: The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor were affected by these treatments and to determine the importance of the 18F-FDG PET method. PATIENTS AND METHODS: Twenty metastatic bone tumor cases were included. Sorafenib and anti-VEGF were added to the standard treatment in cases with widespread metastatic disease at diagnosis or after neoadjuvant chemotherapy showing less than 90% tumor necrosis in the surgical sample. Positron emission tomography (PET) imaging was performed at diagnosis, the preoperative period following neoadjuvant chemotherapy, during postoperative follow-up, and when treatment was discontinued. RESULTS: The primary treatment region median SUVmax level decreased from 7.35 to 2.5 in the living patients (n = 16) while there was no significant decrease in the patients who succumbed to the disease (P < 0.001). Comparison of the pre- and post-treatment metastasis region median SUVmax levels in patients with metastatic involvement showed a decrease from 2.1 to 0 in the surviving patients but only from 4.8 to 3.2 in the deceased patients (P < 0.01). Survival results indicated that 28.6% of the patients receiving classical treatment only died while all the patients receiving additional sorafenib and anti-VEGF survived. CONCLUSIONS: 18F-PET may be a useful technique before and during the follow-up of neoadjuvant treatment in pediatric metastatic bone tumor patients. The addition of sorafenib and anti-VEGF to classical treatment has a favorable contribution to the response and therefore the survival duration. |
format | Online Article Text |
id | pubmed-4904339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-49043392016-06-15 Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? Tacyildiz, Nurdan Tanyildiz, Hikmet Gulsah Dincaslan, Handan Ugur Yavuz, Gulsan Unal, Emel Ozkan, Elgin Soydal, Cigdem Kucuk, Ozlem Yildiz, Yusuf Iran J Pediatr Research Article BACKGROUND: The prognosis is still poor for patients with a metastatic bone tumor and new treatment approaches (anti-VEGF and tyrosine kinase inhibitors vs) are therefore needed. OBJECTIVES: The aim of our study was to evaluate how the primary and metastatic lesions of our patients with a bone tumor were affected by these treatments and to determine the importance of the 18F-FDG PET method. PATIENTS AND METHODS: Twenty metastatic bone tumor cases were included. Sorafenib and anti-VEGF were added to the standard treatment in cases with widespread metastatic disease at diagnosis or after neoadjuvant chemotherapy showing less than 90% tumor necrosis in the surgical sample. Positron emission tomography (PET) imaging was performed at diagnosis, the preoperative period following neoadjuvant chemotherapy, during postoperative follow-up, and when treatment was discontinued. RESULTS: The primary treatment region median SUVmax level decreased from 7.35 to 2.5 in the living patients (n = 16) while there was no significant decrease in the patients who succumbed to the disease (P < 0.001). Comparison of the pre- and post-treatment metastasis region median SUVmax levels in patients with metastatic involvement showed a decrease from 2.1 to 0 in the surviving patients but only from 4.8 to 3.2 in the deceased patients (P < 0.01). Survival results indicated that 28.6% of the patients receiving classical treatment only died while all the patients receiving additional sorafenib and anti-VEGF survived. CONCLUSIONS: 18F-PET may be a useful technique before and during the follow-up of neoadjuvant treatment in pediatric metastatic bone tumor patients. The addition of sorafenib and anti-VEGF to classical treatment has a favorable contribution to the response and therefore the survival duration. Kowsar 2016-03-05 /pmc/articles/PMC4904339/ /pubmed/27307968 http://dx.doi.org/10.5812/ijp.4008 Text en Copyright © 2016, Growth & Development Research Center http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited. |
spellingShingle | Research Article Tacyildiz, Nurdan Tanyildiz, Hikmet Gulsah Dincaslan, Handan Ugur Yavuz, Gulsan Unal, Emel Ozkan, Elgin Soydal, Cigdem Kucuk, Ozlem Yildiz, Yusuf Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? |
title | Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? |
title_full | Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? |
title_fullStr | Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? |
title_full_unstemmed | Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? |
title_short | Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma? |
title_sort | can fluorine-18-fluorodeoxyglucose positron emission tomography be used as a useful method to evaluate the treatment response to neoadjuvant therapy combined with sorafenib and anti-vegf in children diagnosed with metastatical bone sarcoma? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904339/ https://www.ncbi.nlm.nih.gov/pubmed/27307968 http://dx.doi.org/10.5812/ijp.4008 |
work_keys_str_mv | AT tacyildiznurdan canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT tanyildizhikmetgulsah canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT dincaslanhandanugur canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT yavuzgulsan canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT unalemel canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT ozkanelgin canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT soydalcigdem canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT kucukozlem canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma AT yildizyusuf canfluorine18fluorodeoxyglucosepositronemissiontomographybeusedasausefulmethodtoevaluatethetreatmentresponsetoneoadjuvanttherapycombinedwithsorafenibandantivegfinchildrendiagnosedwithmetastaticalbonesarcoma |